Cardiomyopathy Treatment
Cardiomyopathy Treatment
Treatment in cardiomyopathy is rarely aimed at removing the disease. It is aimed at four things at once — relieving symptoms, protecting against complications, slowing what can be slowed, and protecting the family — and the balance between them changes with the type of disease and with the person carrying it. This page sets out which medicines are used in which form and why, the reasoning behind defibrillators rather than the reflex of implanting them, what septal reduction and advanced options involve, and the checkpoints that turn a one-off decision into a plan that holds for years.
What treatment is aiming at
Treatment in cardiomyopathy is rarely aimed at removing the disease. It is aimed at four things at once, and the balance between them shifts with the type, the age and the patient's own priorities.
Breathlessness, fatigue, chest tightness and swelling are all treatable, and exercise capacity is rebuilt deliberately rather than left to recover on its own. The aim is that the patient can still do the things that make the treatment worth having.
Two complications decide the long-term picture: dangerous rhythms, and the congestion and clot formation that follow a struggling pump. Both are anticipated rather than waited for, which is why decisions about anticoagulation and devices are made on risk instead of on events.
For a dilated heart that means the medication which blocks the hormonal drive reshaping the muscle; for amyloidosis it means therapy aimed at the protein; for a fast rhythm it means controlling the rhythm itself. Not every cause can be treated, but the treatable ones have to be found.
Screening relatives, and offering genetic testing where a variant has been identified, is part of treatment rather than an administrative afterthought, because it is directed at people who have not yet had a symptom of any kind.
The order in which these aims are pursued differs by type, and that is the first thing worth understanding about any plan. In obstructive hypertrophic disease the early aim is usually to reduce the obstruction and the symptom burden. In dilated disease it is to start and then to build up the medication that changes the trajectory rather than only the day. In amyloidosis it is to name the protein responsible and treat it specifically, because that therapy exists and is not interchangeable with ordinary heart-failure treatment. Which causes can be treated, and which cannot, is set out on the causes page.
One more thing belongs at the top. A cardiomyopathy plan is a plan with dates on it — a review, a repeat scan, a device question to be revisited, a screening test for a relative — and much of its value lies in keeping those dates rather than in the choice made on any single day.
Medication, chosen by type
There is no single drug for cardiomyopathy. The same classes appear across the types for different reasons, and some drugs that help one form work against another. The table below sets out the logic rather than a prescription: what is used in each form, and what it is being asked to do.
| Type | What is usually used | Why this type needs it |
|---|---|---|
| Dilated cardiomyopathy | An ACE inhibitor, an ARB or an ARNI, a beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor, with a diuretic while there is congestion | The hormonal response to a failing pump keeps reshaping the muscle; blocking it is what changes the trajectory rather than only the symptom of the week |
| Obstructive hypertrophic cardiomyopathy | A beta-blocker first, then a non-dihydropyridine calcium-channel blocker; disopyramide in selected patients; a cardiac myosin inhibitor where appropriate | Slowing the heart and reducing the force of contraction widens the outflow tract and lowers the gradient — the opposite of what a dilated heart needs |
| Non-obstructive hypertrophic cardiomyopathy | Treatment of whatever is actually present: the rhythm, the blood pressure, the stiffness of filling — while avoiding drugs that strip the filling volume away | With no gradient, there is no obstruction to relieve, so the aim shifts to filling, rhythm and the conditions that provoke symptoms |
| Restrictive and infiltrative disease | Diuretics used in small, carefully judged steps, plus therapy directed at the cause: disease-specific treatment for transthyretin amyloidosis, immunosuppression for sarcoidosis and giant-cell disease, iron removal in haemochromatosis | A stiff heart depends on the filling pressure that ordinary diuretic dosing removes, so the dose has to be built around that limit while the cause-specific therapy does the work |
| Arrhythmogenic disease | Beta-blockers and rhythm control, alongside restriction of the exercise types that provoke events | The risk in this form is electrical rather than mechanical, so the drug is chosen for its effect on the rhythm and on the trigger, not for its effect on the pump |
Three rules apply across all of them. The medication plan is a moving plan: doses are built up to what the patient tolerates and what the evidence supports, and they are rechecked when blood pressure, kidney function or the rhythm change rather than left at whatever was written first. Anticoagulation is decided by the rhythm and the atrium, not by the cardiomyopathy label — atrial fibrillation in a dilated or stiff atrium carries a clot risk that has nothing to do with how the muscle was named, and it is the rhythm that decides whether treatment is needed. And in obstructive physiology, drugs that empty the heart or dilate the vessels too aggressively can make the obstruction worse; that is a small change in medication, but not a small thing, and it is one reason follow-up matters even for patients who feel well.
Devices: who is offered protection against a dangerous rhythm
An implantable defibrillator is the treatment patients most often ask about before it has been discussed, and the honest answer is that most people with cardiomyopathy do not have one. The device is offered on the basis of an estimate of risk rather than on the diagnosis itself, and that estimate is assembled from features that have little to do with how the patient feels day to day.
The features the assessment collects, because each of them raises the estimate: a previous dangerous arrhythmia or a cardiac arrest; a fainting spell attributed by the assessment to the heart rather than to a reflex; how thick the wall has become; how much scar the MRI shows; how weak the pump is; the family history, including a sudden death in a close relative; and, in some families, the particular gene variant responsible. No single feature decides on its own, and none of them is a symptom.
The decision has to be reasoned in both directions, which is what makes it a conversation rather than a protocol. A defibrillator can stop a rhythm that would otherwise be fatal — and it also brings lead complications, the possibility of shocks that were not needed, and consequences for driving, work and body image. For a patient whose estimated risk sits in the middle, where most patients sit, the right answer is sometimes to wait, sometimes to treat something else first, and often to revisit the question after the next scan rather than to settle it for good.
Other devices do different jobs. Cardiac resynchronisation therapy is for a weak and dilated heart whose electrical activation is also uncoordinated: pacing both ventricles in step restores a more efficient contraction, and the patients who benefit most are identified by the ECG as much as by the scan. Pacemakers treat slow rhythms, and in obstructive disease they are occasionally used as a secondary measure rather than a primary one. And in a patient recovering from an unstable spell, or waiting for a decision to be made, a wearable defibrillator can bridge the interval — a temporary measure, not a solution.
Surgery and interventional treatment: relieving obstruction, and the advanced options
Where obstructive hypertrophic disease remains symptomatic despite medication, the obstruction itself can be reduced. There are two routes, and both work by widening the path out of the ventricle. Surgical septal myectomy removes a portion of the thickened septum through an open operation, and it has the advantage of letting the surgeon see the mitral valve directly and repair it in the same sitting when the valve is contributing to the obstruction. Alcohol septal ablation creates a small, controlled area of scar in the septum through a catheter, thinning it in the same place without opening the chest. The choice between them is made on anatomy, age, the state of the valve, the presence of coronary disease and the expertise available — not on a general preference.
For a dilated and failing heart, the operations address the consequences rather than the muscle. A valve whose ring has stretched can be repaired, because a leak makes a weak pump weaker. In advanced disease, mechanical support of the left ventricle is considered — as a bridge towards another option or as long-term therapy — and it carries commitments of its own, which are discussed before the decision rather than after it. Where the disease has reached the limit of what medication and support can hold, the patient is referred for assessment for heart transplantation: a pathway with its own criteria and its own timetable, not an outcome to be assumed. Many patients never reach this point; but where it may apply, it is raised early, because assessment takes time, and waiting until it is the only option removes choices rather than adding them.
Decisions of this size are made by a team rather than by one doctor. The imaging cardiologist, the electrophysiologist, the surgeon, the geneticist and the specialist nurse each hold part of the reasoning, and the patient's own priorities — what they want to keep doing, what they are willing to take on — belong inside that discussion rather than in a footnote to it.
The checkpoints: what is reviewed, and why the plan changes
A cardiomyopathy plan is not a single decision but a series of them, and the intervals between the decisions are themselves part of the treatment. Four things are reviewed, each on a rhythm of its own.
- The imaging — repeated when the question changes: after a shift in symptoms, after a treatment is started, before a device or surgical discussion, or at intervals set by the type of disease. Not on a calendar chosen for convenience.
- The rhythm — the ECG and the monitoring repeated on a schedule, because the features that raise the risk of an arrhythmia can change without producing any symptom at all. In some types this is the review that matters most.
- The medication — doses built up to the levels the patient tolerates and the evidence supports, then rechecked whenever blood pressure, kidney function or the rhythm changes.
- The plan itself — the device question, the surgical question, the activity advice and the family screening are all revisited at defined points rather than settled once and filed.
The visits that matter are not only the ones in a hospital. Weight, breathlessness on the usual staircase, and whether the patient can still do what they want to do are measured at home, every day, by the patient — and the reason is that these numbers move days before the way someone feels moves. What to record, and the thresholds at which to report a change rather than wait, are set out on the prevention page, together with the screening plan for relatives and the activity advice that applies to each type.
The questions worth asking before a plan is fixed
Patients who arrive with a written list of questions get better plans, because the questions force the reasoning out into the open where it can be examined. Five are worth keeping on the list, whatever the type.
- Which type is this, and what is the evidence? — the imaging findings, the family history and any genetic result, stated in one sentence rather than left as an impression.
- What is my rhythm risk, and what would have to change for a device to be considered? — the features that raise the estimate, and the threshold, named explicitly instead of being deferred to a later visit.
- Has a treatable cause been excluded, and could one still be missed? — the acquired and infiltrative causes are the ones where treatment differs most between them, so the question is anything but academic.
- What am I allowed to do, and what should I stop? — the answer about exercise is specific to the type and to the risk estimate, and it should come from the team rather than from a general rule found elsewhere.
- What does my family need, and who is going to organise it? — which relatives, which tests, at what age, and who makes contact with them.
A plan that cannot answer these five questions is not yet a plan. And a patient who can restate them is in a much better position to notice when one of the answers has changed — which, in a disease measured over years rather than days, is most of the work.